Adjuvant bidirectional chemotherapy with intraperitoneal pemetrexed combined with intravenous cisplatin for diffuse malignant peritoneal mesothelioma

Gastroenterology Research and Practice

Volumn , Issue , 2012, Pages

  Bijelic, Lana ^a   Stuart, O Anthony ^b   Sugarbaker, Paul ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b MEDSTAR HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; PEMETREXED;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; AREA UNDER THE CURVE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CATHETER INFECTION; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; CYTOREDUCTIVE SURGERY; DRUG SAFETY; FATIGUE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; PERITONEUM MESOTHELIOMA; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE CARE; THROMBOCYTOPENIA;

EID: 84866250856     PISSN: 16876121     EISSN: 1687630X     Source Type: Journal    
DOI: 10.1155/2012/890450     Document Type: Article

References (27)

1. Acherman Y. I. Z., Welch L. S., Bromley C. M., Sugarbaker P. H., Clinical presentation of peritoneal mesothelioma. Tumori 2003 89 3 269 273 2-s2.0-0041426454 (Pubitemid 37014117)
2. Antman K. H., Blum R. H., Greenberger J. S., Multimodality therapy for malignant mesothelioma based on a study of natural history. American Journal of Medicine 1980 68 3 356 362 2-s2.0-0018889197 (Pubitemid 10130375)
3. Averbach A. M., Sugarbaker P. H., Peritoneal mesothelioma: treatment approach based on natural history. Cancer Treatment and Research 1996 81 193 211 2-s2.0-0029683283
4. Chailleux E., Dabouis G., Pioche D., De Lajartre M., De Lajartre A. Y., Rembeaux A., Germaud P., Prognostic factors in diffuse malignant pleural mesothelioma. A study of 167 patients. Chest 1988 93 1 159 162 2-s2.0-0023853545 (Pubitemid 18037276)
5. Antman K., Shemin R., Ryan L., Klegar K., Osteen R., Herman T., Lederman G., Corson J., Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 19651985. Journal of Clinical Oncology 1988 6 1 147 153 2-s2.0-0023840617 (Pubitemid 18040002)
6. Sridhar K. S., Doria R., Raub W. A. Jr., Thurer R. J., Saldana M., New strategies are needed in diffuse malignant mesothelioma. Cancer 1992 70 12 2969 2979 2-s2.0-0026442078 10.1002/1097-0142(19921215)70:122969::AID- CNCR2820701239>3.0.CO;2-A
7. Sugarbaker P. H., Welch L. S., Mohamed F., Glehen O., A review of peritoneal mesothelioma at the Washington Cancer Institute. Surgical Oncology Clinics of North America 2003 12 3 605 621 2-s2.0-0042744851 10.1016/S1055-3207(03)00045-0 (Pubitemid 36920088)
8. Yan T. D., Brun E. A., Carlos A., Haveric N., Chang D., Sugarbaker P. H., Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma. Annals of Surgical Oncology 2007 14 1 41 49 2-s2.0-33845631273 10.1245/s10434-006-9169-7 (Pubitemid 44954269)
9. Feldman A. L., Libutti S. K., Pingpank J. F., Bartlett D. L., Beresnev T. H., Mavroukakis S. M., Steinberg S. M., Liewehr D. J., Kleiner D. E., Alexander H. R., Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. Journal of Clinical Oncology 2003 21 24 4560 4567 2-s2.0-1542648318 10.1200/JCO.2003.04.150 (Pubitemid 46594027)
10. Nonaka D., Kusamura S., Baratti D., Casali P., Cabras A. D., Younan R., Rosai J., Deraco M., Diffuse malignant mesothelioma of the peritoneum: a clinicopathologic study of 35 patients treated locoregionally at a single institution. Cancer 2005 104 10 2181 2188 2-s2.0-27644476267 10.1002/cncr.21239 (Pubitemid 41579965)
11. Loggie B. W., Fleming R. A., McQuellon R. P., Russell G. B., Geisinger K. R., Levine E. A., Prospective trial for the treatment of malignant peritoneal mesothelioma. American Surgeon 2001 67 10 999 1003 2-s2.0-0035489804 (Pubitemid 33738134)
12. Brigand C., Monneuse O., Mohamed F., Sayag-Beaujard A. C., Isaac S., Gilly F. N., Glehen O., Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study. Annals of Surgical Oncology 2006 13 3 405 412 2-s2.0-32844472178 10.1245/ASO.2006.05.041 (Pubitemid 43255925)
13. Baratti D., Kusamura S., Cabras A. D., Dileo P., Laterza B., Deraco M., Diffuse malignant peritoneal mesothelioma: failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC). Annals of Surgical Oncology 2009 16 2 463 472 2-s2.0-59449109253 10.1245/s10434-008-0219-1
14. Vogelzang N. J., Rusthoven J. J., Symanowski J., Denham C., Kaukel E., Ruffie P., Gatzemeier U., Boyer M., Emri S., Manegold C., Niyikiza C., Paoletti P., Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. Journal of Clinical Oncology 2003 21 14 2636 2644 2-s2.0-0041629528 10.1200/JCO.2003.11.136 (Pubitemid 46606305)
15. Jänne P. A., Wozniak A. J., Belani C. P., Keohan M. L., Ross H. J., Polikoff J. A., Mintzer D. M., Taylor L., Ashland J., Ye Z., Monberg M. J., Obasaju C. K., Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. Clinical Lung Cancer 2005 7 1 40 46 2-s2.0-23844441578 (Pubitemid 41150472)
16. Nuernberg B., Kohlbrenner M., Faulkner R., Furst D., Rapid quantitation of methotrexate and its metabolites in human serum, urine and bile, using solid-phase extraction and high-performance liquid chromatography. Journal of Chromatography 1989 487 2 476 482 2-s2.0-0024344689 (Pubitemid 19147220)
17. Yan T. D., Brun E. A., Cerruto C. A., Haveric N., Chang D., Sugarbaker P. H., Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma. Annals of Surgical Oncology 2007 14 1 41 49 2-s2.0-33845631273 10.1245/s10434-006-9169-7 (Pubitemid 44954269)
18. Chua T. C., Yan T. D., Morris D. L., Peritoneal mesothelioma: current understanding and management. Canadian Journal of Surgery 2009 52 1 59 64 2-s2.0-62249128130
19. Hassan R., Alexander R., Antman K., Boffetta P., Churg A., Coit D., Hausner P., Kennedy R., Kindler H., Metintas M., Mutti L., Onda M., Pass H., Premkumar A., Roggli V., Sterman D., Sugarbaker P., Taub R., Verschraegen C., Current treatment options and biology of peritoneal mesothelioma: Meeting summary of the first NIH peritoneal mesothelioma conference. Annals of Oncology 2006 17 11 1615 1619 2-s2.0-33750591484 10.1093/annonc/mdl060 (Pubitemid 44680879)
20. Yan T. D., Deraco M., Baratti D., Kusamura S., Elias D., Glehen O., Gilly F. N., Levine E. A., Shen P., Mohamed F., Moran B. J., Morris D. L., Chua T. C., Piso P., Sugarbaker P. H., Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. Journal of Clinical Oncology 2009 27 36 6237 6242 2-s2.0-74949123203 10.1200/JCO.2009.23.9640
21. Schultz R. M., Chen V. J., Bewley J. R., Roberts E. F., Shih C., Dempsey J. A., Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs. Seminars in Oncology 1999 26 2 68 73 2-s2.0-0032914341 (Pubitemid 29218031)
22. Mendelsohn L. G., Shih C., Chen V. J., Habeck L. L., Gates S. B., Shackelford K. A., Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis. Seminars in Oncology 1999 26 2 supplement 6 42 47 2-s2.0-0032950347 (Pubitemid 29218027)
23. Dedrick R. L., Myers C. E., Bungay P. M., Devita V. T., Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treatment Reports 1978 62 1 1 11 2-s2.0-0017853566 (Pubitemid 8278518)
24. Pestieau S. R., Stuart O. A., Sugarbaker P. H., Multi-targeted antifolate (MTA): pharmacokinetics of intraperitoneal administration in a rat model. European Journal of Surgical Oncology 2000 26 7 696 700 2-s2.0-0033636144 10.1053/ejso.2000.0983
25. Armstrong D. K., Bundy B., Wenzel L., Huang H. Q., Baergen R., Lele S., Copeland L. J., Walker J. L., Burger R. A., Mackey D., Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New England Journal of Medicine 2006 354 1 34 43 2-s2.0-30044438368 10.1056/NEJMoa052985 (Pubitemid 43048949)
26. Walker J. L., Armstrong D. K., Huang H. Q., Fowler J., Webster K., Burger R. A., Clarke-Pearson D., Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecologic Oncology 2006 100 1 27 32 2-s2.0-29144462090 10.1016/j.ygyno.2005. 11.013 (Pubitemid 41815045)
27. Sugarbaker R. H., Gianola F. J., Speyer J. C., Prospective, randomized trial of intravenous versus intraperitoneal 5-fluorouracil in patients with advanced primary colon or rectal cancer. Surgery 1985 98 3 414 422 2-s2.0-0022339910 (Pubitemid 16143766)